Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran 27 October
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy 25 September
